PCLX-001 |
| Catalog No.GC65891 |
PCLX-001은 각각 5nM(NMT1) 및 8nM(NMT2)의 IC50을 갖는 경구 활성 소분자 이중 NMT(N-myristoyltransferase) 억제제입니다. 821d96072c2d58d8970e76f526b0f6b8PCLX-001은 항종양 활성을 나타내며 초기 BCR(B-세포 수용체) 신호 전달을 억제하여 B-세포 악성 종양 연구에 사용할 수 있습니다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1215011-08-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. PCLX-001 exhibits anti-tumor activity and inhibits early B-cell receptor (BCR) signaling, can be used to B-cell malignancies research[1][2].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *